bioRxiv Science⌕ Search

Biology subjects

Irvine, E. B.

Publications and source records attributed to Irvine, E. B..

11 recordsLinked to original sources

Predicting viral host range for reverse zoonosis surveillance

Zoonotic transmission of viruses has triggered major outbreaks throughout history. However, human-to-animal transmission, or reverse zoonotic transmission, also represents an underappreciated public health threat. Reverse zoonoses can establish novel animal reservoirs that fuel viral evolution and enable eventual spillback into humans, underscoring the importance of defining viral host range. Current approaches for host range prediction are limited. Experimental methods are retrospective and rely on brute-force testing in a small number of models, whereas computational approaches often lack experimental grounding. Here, we present a platform that integrates high-throughput experimental screening with deep learning to predict viral host range from sequence. We screened a yeast-displayed SARS-CoV-2 receptor-binding domain library against 15 ACE2 orthologs from diverse species, and deep sequenced the ACE2-binding and non-binding populations to generate an atlas of 8.8 million unique RBD:ACE2 interaction measurements. These data were used to train a transformer-based deep learning model that predicts RBD:ACE2 compatibility across animal species from sequence alone, and generalizes in a zero-shot manner to ACE2 orthologs not observed during training. Critically, the model pairs each prediction with a distance-based uncertainty estimate, allowing hundreds of candidate species to be triaged by both predicted host compatibility and confidence. This framework enables the rapid prioritization of animal species for SARS-CoV-2 surveillance and provides a general strategy for anticipating viral host range.

bioengineering↗

Generative design of antibody Fc-variants with synthetic and programmable functional profiles

Beyond antigen recognition, antibodies direct diverse immune effector functions through their constant (Fc) domain. While the Fc domain is central to antibody biology and therapeutic efficacy, our understanding of how Fc sequence encodes function remains limited, as most of Fc sequence space has not been experimentally mapped or linked to Fc-receptor engagement. Furthermore, the extensive overlap in Fc-receptor binding sites on the Fc domain has impeded efforts to engineer antibodies with tailored, multi-receptor engagement profiles that can precisely control downstream immunity. Here we introduce a novel framework for Fc engineering that integrates protein engineering with deep learning to rationally predict and engineer antibody Fc function. Using a yeast-based, aglycosylated Fc display system, we performed deep mutational scanning across the entire human IgG1 Fc domain, allowing the rational design of a diverse combinatorial library of more than 108 Fc-variants. This library was sorted based on binding to a panel of eight canonical Fc-receptors, and the resulting populations were deep sequenced to generate a high-quality dataset comprising millions of unique Fc sequences annotated with their respective Fc-receptor binding profiles. Deep learning-based classifiers trained on this dataset accurately predicted Fc-receptor binding activity from Fc sequence across all Fc-receptors tested. We further developed FcGPT, a domain-specific autoregressive protein language model pre-trained on over three million unique Fc sequences, and refined by post-training through reinforcement learning with experimental feedback (RLXF) and synthetic verifiers. FcGPT enables the computational design of novel Fc-variants with user-defined Fc-receptor binding profiles, providing a foundational tool for understanding and programming antibody-mediated immunity.

bioengineering↗

High-throughput cell-free profiling of SARS-CoV-2 RBD variants enables rapid and quantitative in vitro affinity landscape mapping

SARS-CoV-2 variants continue to threaten public health, necessitating the study of cumulative and epistatic effects of receptor-binding domain (RBD) mutations on antibody evasion. We present a high-throughput platform combining cell-free protein synthesis and microfluidics to quantify the affinity of a large number of RBD triplet mutants covering the evolutionary space between wild-type and Omicron against two therapeutic antibodies and one engineered binder. Using rapid in vitro gene assembly and cell-free synthesis, we expressed 518 RBD variants and obtained 31,740 quantitative affinity measurements to generate three comprehensive binding energy landscapes. This approach enables rapid and large-scale in vitro affinity profiling and machine learning-based predictions, providing a valuable tool for studying emerging variants.

systems biology↗

Simple high-throughput encoding of deep mutational scanning libraries by oligo-based Golden Gate assembly

Control over mutational library diversity is an essential consideration when engineering proteins, but is often fraught with trade-offs between diversity, specificity, and affordability. Contemporary library assembly approaches often incorporate oligonucleotide pool synthesis to achieve affordable, precise mutagenesis; however, these oligos are often reliant on complex designs to facilitate downstream PCR and/or restriction digests. Direct hybridisation of oligo pools is an overlooked strategy to simplify mutagenesis, especially when paired with a type IIS restriction cloning approach. We validate this approach by designing, hybridising, and deep sequencing single and dual substitution CDR region parts derived from nanobody GA10. Assembly of these parts into a full-length nanobody CDS facilitated the phage display of variant libraries for affinity maturation against its cyclic peptide target. Variants identified through enrichment analysis were expressed in isolation and yielded improved affinities by more than 100-fold. Recent advances in machine learning have successfully inferred improved variants outside of screened library space, but require controlled, multi-mutant libraries. The library assembly approach outlined in this research is well-suited for such approaches.

synthetic biology↗

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is a leading cause of death by an infectious disease globally, with no efficacious vaccine. Antibodies are implicated in Mtb control, but the mechanisms of antibody action remain poorly understood. We assembled a library of TB monoclonal antibodies (mAb) and screened for the ability to restrict Mtb in mice, identifying protective antibodies targeting known and novel antigens. To dissect the mechanism of mAb-mediated Mtb restriction, we optimized a protective lipoarabinomannan-specific mAb through Fc-swapping. In vivo analysis of these Fc-variants revealed a critical role for Fc-effector function in Mtb restriction. Restrictive Fc-variants altered distribution of Mtb across innate immune cells. Single-cell transcriptomics highlighted distinctly activated molecular circuitry within innate immune cell subpopulations, highlighting early activation of neutrophils as a key signature of mAb-mediated Mtb restriction. Therefore, improved antibody-mediated restriction of Mtb is associated with reorganization of the tissue-level immune response to infection and depends on the collaboration of antibody Fab and Fc.

immunology↗

Markov Field network integration of multi-modal data predicts effects of immune system perturbations on intravenous BCG vaccination in macaques

Analysis of multi-modal datasets can identify multi-scale interactions underlying biological systems, but can be beset by spurious connections due to indirect impacts propagating through an unmapped biological network. For example, studies in macaques have shown that BCG vaccination by an intravenous route protects against tuberculosis, correlating with changes across various immune data modes. To eliminate spurious correlations and identify critical immune interactions in a public multi-modal dataset (systems serology, cytokines, cytometry) of vaccinated macaques, we applied Markov Fields (MF), a data-driven approach that explains vaccine efficacy and immune correlations via multivariate network paths, without requiring large numbers of samples (i.e. macaques) relative to multivariate features. Furthermore, we find that integrating multiple data modes with MFs helps to remove spurious connections. Finally, we used the MF to predict outcomes of perturbations at various immune nodes, including a B-cell depletion that induced network-wide shifts without reducing vaccine protection, which we validated experimentally.

systems biology↗

Deep learning-guided selection of antibody therapies with enhanced resistance to current and prospective SARS-CoV-2 Omicron variants

Most COVID-19 antibody therapies rely on binding the SARS-CoV-2 receptor binding domain (RBD). However, heavily mutated variants such as Omicron and its sublineages, which are characterized by an ever increasing number of mutations in the RBD, have rendered prior antibody therapies ineffective, leaving no clinically approved antibody treatments for SARS-CoV-2. Therefore, the capacity of therapeutic antibody candidates to bind and neutralize current and prospective SARS-CoV-2 variants is a critical factor for drug development. Here, we present a deep learning-guided approach to identify antibodies with enhanced resistance to SARS-CoV-2 evolution. We apply deep mutational learning (DML), a machine learning-guided protein engineering method to interrogate a massive sequence space of combinatorial RBD mutations and predict their impact on angiotensin-converting enzyme 2 (ACE2) binding and antibody escape. A high mutational distance library was constructed based on the full-length RBD of Omicron BA.1, which was experimentally screened for binding to the ACE2 receptor or neutralizing antibodies, followed by deep sequencing. The resulting data was used to train ensemble deep learning models that could accurately predict binding or escape for a panel of therapeutic antibody candidates targeting diverse RBD epitopes. Furthermore, antibody breadth was assessed by predicting binding or escape to synthetic lineages that represent millions of sequences generated using in silico evolution, revealing combinations with complementary and enhanced resistance to viral evolution. This deep learning approach may enable the design of next-generation antibody therapies that remain effective against future SARS-CoV-2 variants.

immunology↗

Humoral correlates of protection against Mycobacterium tuberculosis following intravenous Bacille Calmette-Guerin vaccination in rhesus macaques

Altering the route of Bacille Calmette-Guerin (BCG) immunization from low-dose intradermal vaccination to high-dose intravenous (IV) vaccination resulted in a high level of protection against Mycobacterium tuberculosis (Mtb) infection, providing an opportunity to uncover immune correlates and mechanisms of protection. In addition to strong T cell immunity, IV BCG vaccination was associated with a robust expansion of humoral immune responses that tracked with bacterial control. However, given the near complete protection afforded by high-dose IV BCG immunization, a precise correlate of immune protection was difficult to define. Here we leveraged plasma and bronchoalveolar lavage fluid (BAL) from a cohort of rhesus macaques that received decreasing doses of IV BCG and aimed to define the correlates of immunity across macaques that experienced immune protection or breakthrough infection following Mtb challenge. We show an IV BCG dose-dependent induction of mycobacterial-specific humoral immune responses, both in the plasma and in the airways. Moreover, antibody responses at peak immunogenicity significantly predicted bacterial control following challenge. Multivariate analyses revealed antibody-mediated complement and NK cell activating humoral networks as key functional signatures associated with protective immunity. Collectively, this work extends our understanding of humoral biomarkers and potential mechanisms of IV BCG mediated protection against Mtb.

immunology↗

Protective intravenous BCG vaccination induces enhanced immune signaling in the airways

Intradermal (ID) Bacillus Calmette-Guerin (BCG) is the most widely administered vaccine in the world. However, ID-BCG fails to achieve the level of protection needed in adults to alter the course of the tuberculosis epidemic. Recent studies in non-human primates have demonstrated high levels of protection against Mycobacterium tuberculosis (Mtb) following intravenous (IV) administration of BCG. However, the protective immune features that emerge following IV BCG vaccination remain incompletely defined. Here we used single-cell RNA-sequencing (scRNAseq) to transcriptionally profile 157,114 unstimulated and purified protein derivative (PPD)-stimulated bronchoalveolar lavage (BAL) cells from 29 rhesus macaques immunized with BCG across routes of administration and doses to uncover cell composition-, gene expression-, and biological network-level signatures associated with IV BCG-mediated protection. Our analyses revealed that high-dose IV BCG drove an influx of polyfunctional T cells and macrophages into the airways. These macrophages exhibited a basal activation phenotype even in the absence of PPD-stimulation, defined in part by IFN and TNF- signaling up to 6 months following BCG immunization. Furthermore, intercellular immune signaling pathways between key myeloid and T cell subsets were enhanced following PPD-stimulation in high-dose IV BCG-vaccinated macaques. High-dose IV BCG also engendered quantitatively and qualitatively stronger transcriptional responses to PPD-stimulation, with a robust Th1-Th17 transcriptional phenotype in T cells, and augmented transcriptional signatures of reactive oxygen species production, hypoxia, and IFN-{gamma} response within alveolar macrophages. Collectively, this work supports that IV BCG immunization creates a unique cellular ecosystem in the airways, which primes and enables local myeloid cells to effectively clear Mtb upon challenge.

immunology↗

Fc-engineered antibodies leverage neutrophils to drive control of Mycobacterium tuberculosis

Novel vaccination and therapeutic strategies are urgently needed to mitigate the tuberculosis (TB) epidemic. While extensive efforts have focused on potentiating cell-mediated immunity to control Mycobacterium tuberculosis (Mtb) infection, less effort has been invested in exploiting the humoral immune system to combat Mtb. Emerging data point to a role for antibodies in microbial control of Mtb, however the precise mechanism(s) of this control remain incompletely understood. Here we took an antibody Fc-engineering approach to determine whether Fc-modifications could improve the ability of antibodies to restrict Mtb, and to define Fc-mediated mechanism(s) antibodies leverage for this restriction. Using an antibody specific to the capsular polysaccharide -glucan, we engineer a panel of Fc variants to augment or dampen select antibody effector functions, rationally building antibodies with enhanced capacity to promote Mtb restriction in a human whole blood model of infection. Surprisingly, restrictive Fc-engineered antibodies drive Mtb control in a neutrophil, not monocyte, dependent manner. Using single cell RNA sequencing, we show that restrictive antibodies promote neutrophil survival and expression of cell intrinsic antimicrobial programs. These data provide a roadmap for exploiting Fc-engineered antibodies as a novel class of TB therapeutics able to harness the protective functions of neutrophils to achieve disease control.

immunology↗

Robust IgM responses following vaccination are associated with prevention of Mycobacterium tuberculosis infection in macaques

Development of an effective tuberculosis (TB) vaccine has suffered from an incomplete understanding of the correlates of protection against Mycobacterium tuberculosis (Mtb). However, recent work has shown that compared to standard intradermal Bacille Calmette-Guerin (BCG) vaccination, intravenous (IV) BCG vaccination provides nearly complete protection against TB in rhesus macaques. While studies have focused on cellular immunity in this setting, the antibody response elicited by IV BCG vaccination remains incompletely defined. Using an agnostic antibody profiling approach, here we show that IV BCG drives superior antibody responses in the plasma and the bronchoalveolar lavage fluid (BAL). While IV BCG immunization resulted in the expansion of a robust IgM, IgG, IgA, Fc-receptor binding antibodies, and antibody effector functions in the BAL, IgM titers were among the strongest markers of reduced bacterial burden in the plasma and BAL of BCG immunized animals. Moreover, IgM immunity was also enriched among animals receiving protective vaccination with an attenuated Mtb strain. Finally, a LAM-specific IgM monoclonal antibody reduced Mtb survival in vitro. Collectively, these data highlight the potential importance of IgM responses as a marker and as a functional mediator of protection against TB.

immunology↗